Clinical Studies

Two clinical studies, including one in Australia, using double-blind placebo-controlled design (the gold standard for clinical studies) have been conducted on BreathMor. In both studies, researchers found that BreathMor improves the quality of life concerning daily activities, nasal and eye symptoms. Researchers also found that BreathMor improves work productivity and does not affect sleep.
Reference
Clinical Study : Walanj, S., et al., Efficacy and safety of intranasal cinnamon bark extract in seasonal allergic rhinitis patients: A double-blind placebo-controlled pilot study. Journal of Herbal Medicine, 2014. 4: p. 37-47.
Clinical Study : Steels E. A randomized, double-blind, prospective, parallel study to assess effect of IND02 nasal spray (standardized hydroalcoholic extract of Cinnamomum zeylanicum bark) in reducing symptoms of Seasonal Allergic Rhinitis. Unpublished clinical study report; 2018. Project No. IND02-AR.
Pre-Clinical Study : Aswar, U., et al., Anti-allergic Effect of Intranasal Administration of Type-A Procyanidine Polyphenols Based Standardized Extract of Cinnamon Bark in Ovalbumin sensitized BALB/c Mice. Phytotherapy Research, 2015. 29: p. 423–433.
Pre-Clinical Study : Kandhare, A.D., et al., Ameliorative effects of type-A procyanidins polyphenols from cinnamon bark in compound 48/80-induced mast cell degranulation. Anatomy & Cell Biology, 2017. 50(4): p. 275-283.

  • The Mechanism of Action

    BreathMor fights hayfever by preventing the allergic reaction itself. BreathMor also inhibits allergic inflammation. The scientific studies confirm that the active ingredient of BreathMor inhibits mast cell degranulation. To know more about the mechanism of action, please read the above scientific papers.

  • Patent

    BreathMor is patented in Australia. BreathMor Australia patent number is AU2011284357. No other product in Australia has the same formula or active ingredient of BreathMor.

  • Metered Doses

    BreathMor uses advanced technology for its metered pump. This ensures precise dose delivery every time BreathMor is used. The tip seal mechanism prevents contamination from external environment. The anti-clogging nozzle prevents evaporation and clogging of the formulation.

  • No Effect on Sleep

    Hayfever often affects sleep, causes fatigue, leads to irritability, and hampers work productivity. BreathMor has no impact on sleep. Additionally, BreathMor improves work productivity and quality of life in hayfever patients.

  • Gluten, Sugar and Lactose-free

    BreathMor has no added Gluten, Sugar and Lactose.

Rhinoconjuctivitis Quality of Life Questionnaire (RQLQ)

The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ®) is an internationally accepted standard which was developed to measure the quality of life parameters in hayfever.

The RQLQ® has 28 questions in 7 areas (activity limitation, sleep problems, nose symptoms, eye symptoms, non-nose/eye symptoms, practical problems and emotional function). The overall RQLQ® score is the average of all 28 responses, and the individual domain scores are the averages of the items in those areas. BreathMor has been clinically shown to improve the RQLQ® score in hayfever patients.

Reference
Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exper Allergy 1991; 21: 77-83.
Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996; 98: 843-845.